Savitha Balaraman, MD
Medical Oncology · Madison Heights, MINPI 1083696694
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Merck at 37.3% of the total. Reporting peaked in 2023 at $3,572 and has fallen 95.8% since, to $152 in 2025.
Across 161 payments — averaging $48.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- Immunomedics, Inc.$2K
- Pfizer$356
- Amgen$322
- Johnson & Johnson$246
- Seagen Inc.$222
- plus $2K from 30 others
Across 65 payments — averaging $4011.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$80K
- Epizyme, Inc.$32K
- AstraZeneca$29K
- Novocure GmbH$28K
- Morphosys AG$20K
- Bayer$16K
- plus $55K from 5 others
What the payments were for
- Speaking & faculty fees$4,23554%
- Travel & lodging$250%
- Food & beverage$3,13140%
- Education$3835%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 9 | $2,899 |
| Immunomedics, Inc. | 1 | $1,575 |
| Pfizer | 23 | $356 |
| Amgen | 11 | $322 |
| Johnson & Johnson(2 entities) | 4 | $246 |
| Seagen Inc. | 10 | $222 |
| Novartis | 11 | $218 |
| AVEO Pharmaceuticals, Inc. | 13 | $196 |
| Astellas Pharma US Inc | 10 | $162 |
| Gilead(2 entities) | 11 | $157 |
| Genentech USA, Inc. | 9 | $146 |
| Foundation Medicine, Inc. | 2 | $142 |
| Avyxa Pharma, LLC | 1 | $132 |
| Exelixis Inc. | 1 | $122 |
| AstraZeneca | 4 | $97 |
| Mirati Therapeutics, Inc. | 5 | $85 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Nestle Healthcare Nutrition Inc. | 3 | $65 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| AMAG Pharmaceuticals, Inc. | 4 | $52 |
| Sanofi | 2 | $51 |
| Pharmaessentia USA Corporation | 2 | $47 |
| EMD Serono, Inc. | 3 | $40 |
| Blueprint Medicines Corporation | 2 | $37 |
| Bristol Myers Squibb | 2 | $34 |
| Ipsen Biopharmaceuticals, Inc | 2 | $34 |
| Morphosys, US Inc. | 2 | $32 |
| Array Biopharma Inc | 2 | $31 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Myovant Sciences Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$2,774
- Trodelvy$1,575
- FOUNDATIONONE$132
- FOUNDATIONONE HEME$132
- FOUNDATIONONE CDX$132
- FOUNDATIONFOCUS$132
- FOUNDATIONONE LIQUID$132
- LUTRATE DEPOT$132
- FRINDOVYX$132
- AXTLE$132
- Posfrea$132
- Docivyx$132
- DARZALEX$122
- Cabometyx$122
- Vectibix$102
How this compares
$7,773 in reported general payments places this provider in the 65th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 140 | $1,981,954 |
| IbrancePalbociclib | 35 | $537,247 |
| Lenalidomide | 26 | $405,219 |
| KisqaliRibociclib Succinate | 26 | $362,787 |
| VerzenioAbemaciclib | 21 | $300,960 |
| RevlimidLenalidomide | 12 | $234,756 |
| TasignaNilotinib Hcl | 14 | $210,380 |
| ImbruvicaIbrutinib | 12 | $192,378 |
| BrukinsaZanubrutinib | 13 | $189,821 |
| InqoviDecitabine/Cedazuridine | 12 | $95,067 |
| EliquisApixaban | 68 | $54,490 |
| Abiraterone Acetate | 55 | $52,888 |
| XareltoRivaroxaban | 42 | $32,271 |
| Deferasirox | 13 | $22,125 |
| Anastrozole | 416 | $19,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $162 | $1,981,954140 claims |
| PfizerIbrance, Eliquis | $356 | $591,738103 claims |
| NovartisKisqali, Tasigna | $218 | $573,16740 claims |
| Bristol Myers SquibbRevlimid | $34 | $234,75612 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $24 | $192,37812 claims |
| Taiho Oncology, Inc.Inqovi | $22 | $95,06712 claims |
| Johnson & JohnsonXarelto | $246 | $32,27142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 170 medical oncology providers in Michigan.
Other medical oncology in Madison Heights
- Harry ErbaAnn Arbor$1.1M
- Philip PhilipDetroit$494K
- Shirish GadgeelDetroit$413K
- Patricia Lo RussoDetroit$322K
- Ammar SukariDetroit$273K
- Sami BrakeGrand Rapids$251K
- Frank WeinbergAnn Arbor$195K
- Wajahat KhanGrosse Pointe Woods$190K
- Charles SchifferDetroit$165K
- Francis WordenAnn Arbor$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.